For many early‑stage biotech founders, the first real due diligence experience happens when an investor requests it. By then, the clock is ticking, the data room is open, and the sponsor’s team is scrambling to assemble documents, justify decisions, and respond to gaps the investor has already spotted.
This is the worst possible time to discover a problem.
Mock due diligence — also known as gap analysis — is the single most effective way to avoid this scenario. Yet it remains one of the most consistently overlooked steps in early drug development. Startups often underestimate it, delay it, or assume they can “figure it out later.” Investors, meanwhile, assume the opposite: that founders have already scrutinised their programme, challenged their assumptions, and mapped out the risks.
The result is a painful mismatch in expectations — and often, a missed opportunity.
Why Mock Due Diligence Matters
Before investors ever open a data room, they already have a clear sense of what a prepared startup should look like. They expect founders to understand their own risks, to have interrogated their development plan, and to be able to explain the rationale behind every major decision. Mock due diligence is the mechanism that makes this possible.
It is not a rehearsal. It is a structured, expert‑led simulation of the real investor review process — one designed to expose weaknesses early and strengthen the programme before external scrutiny begins. Its purpose is straightforward:
- Identify red flags before investors do
- Reveal gaps founders didn’t know they had
- Provide solutions and corrective actions
- Strengthen the development plan
- Build a credible, investor‑ready narrative
In short, mock due diligence gives founders the chance to resolve issues while they are still manageable — and to enter fundraising with clarity rather than uncertainty.
Startups Don't Know What They Don't Know
One of the most common challenges in early‑stage drug development is that founders often have deep scientific expertise but limited exposure to the full breadth of activities required to bring a therapy to the clinic. What feels robust internally can look incomplete or risky when viewed through an investor’s lens.
Academic founders know their science deeply — but often lack experience in:
- CMC development
- Dose selection and PK translation
- Regulatory expectations
- Non-clinical development and expertise on translation to humans
- Clinical planning
- Data room structure
- Competitive positioning
Lean biotech teams face similar challenges. They may have strong scientific leadership but limited operational depth. They may not realise that their CMC package is immature, their dose justification incomplete, or their timelines unrealistic.
Mock due diligence exposes these blind spots early — long before they become reasons for an investor to walk away.
The Gaps That Appear Again and Again
Across more than 150 due diligence and gap analyses, Venn has seen the same issues surface repeatedly:
- Immature CMC package. Investors consistently focus on manufacturing readiness. If the process is underdeveloped, impurities poorly characterised, or formulation work incomplete, confidence drops immediately.
- Weak dose justification. Founders often cannot clearly explain how they selected their first‑in‑human or Phase II dose. Investors notice this instantly.
- Unrealistic timelines. Especially when early shortcuts — such as accelerated Australian Phase I entry — create downstream rework for EU/US submissions.
- Poorly structured data rooms. A disorganised data room hints to a poor programme organization. Investors interpret it as a lack of operational maturity.
- Missing expertise. If the team lacks CMC, regulatory, or clinical depth, investors question whether the programme can be executed at all.
These are not minor issues. They directly influence whether an investor sees a programme as fundable.
Mock Due Diligence Builds Credibility
Investors are far more scientifically sophisticated than many founders assume. They are not generalists — they are deeply experienced, technically literate, and capable of asking the right questions at the right depth. They expect founders to demonstrate:
- Transparency
- Realistic cost and timeline planning
- Understanding of risk
- Ability to justify decisions
- Awareness of gaps and how to fix them
Mock due diligence prepares founders for these conversations. It helps them communicate clearly, anticipate questions, and present a coherent, credible story.
A Better Way to Prepare for Fundraising
Mock due diligence is not just about avoiding mistakes — it is about accelerating success. Startups that invest in gap analysis:
- Enter fundraising with confidence
- Present a polished, investor‑ready narrative
- Demonstrate maturity and preparedness
- Reduce the risk of late‑stage surprises
- Move faster than competitors
In a world in which investors are increasingly selective, mock due diligence becomes a strategic advantage — not a luxury.
The Bottom Line
Startups often treat due diligence as something that happens to them. It is something they can — and should — prepare for proactively. Mock due diligence gives founders the clarity, structure, and risk intelligence they need to succeed in a demanding investment environment.
Skipping it is easy.
Recovering from the consequences is not.
Authors
This article was collaborated on by Katsu Mihara, Erik Gout, and Arthur Noach
